Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger

By Keith Speights - Updated Aug 14, 2019 at 12:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.

Mylan ( MYL ) delivered disappointing results across the board in April when the drugmaker provided its first-quarter update. Investors were left wondering what Mylan might do to turn things around. They now have an answer.

On Monday, Mylan and Pfizer announced plans to combine Pfizer's Upjohn unit with Mylan in an all-stock transaction. Pfizer's shareholders will own 57% of the combined company, with Mylan's shareholders owning 43%.

This big story overshadowed Mylan's other news: The drugmaker reported its second-quarter results before the market opened on Monday. Here's what you need to know about how Mylan performed in the second quarter. 

Pills stuck together to form a dollar sign

Image source: Getty Images.

Mylan results: The raw numbers


Q2 2019 

Q2 2018 



$2.85 billion $2.81 billion


Net income (loss)

($168.5 million) $37.5 million


Adjusted earnings per share (EPS)

$1.03 $1.07


Data source: Mylan.

What happened with Mylan this quarter?

Mylan's fortunes improved in the second quarter in the important North American market. Net sales for the company's North American segment increased by 2% year over year to $1.02 billion. This growth was driven in large part by higher sales of Fulphila (Mylan's biosimilar to Neulasta) and by Wixela Inhub (Mylan's generic version of Advair).

The story wasn't as good in Europe, though, at least not at first glance. Mylan reported that net sales from its Europe segment were $989.6 million, down $1 million from the prior-year period. However, the main culprit was currency headwinds. On a constant-currency basis, Mylan's European net sales increased by 6% year over year, thanks primarily to the launches of new products such as Hulio, its biosimilar to Humira.

Mylan's strongest performance in the second quarter came from geographic regions outside of North America and Europe. The company's "rest of world" segment generated net sales of $805.2 million, up around 5% from the prior-year period on a reported basis. On a constant-currency basis, the segment's net sales increased by 10% year over year. Mylan attributed the growth primarily to higher sales in China and new products launched in Australia and emerging markets. 

Although Mylan's revenue increased in the second quarter, its bottom line deteriorated for several reasons. The company's gross profit fell due in part to amortization from product acquisitions and expenses related to the recall of Valsartan products. Mylan's operating expenses also increased, primarily as a result of higher spending on selling and marketing activities and higher litigation expenses.

What management had to say

Mylan CEO Heather Bresch stated, "Mylan's second-quarter performance was strong as we delivered or exceeded on expectations across all financial metrics. In addition, based upon our strong execution against our plan, we remain on track to deliver on our 2019 guidance."

CFO Ken Parks added:

Mylan continues to generate strong cash flow with approximately $724 million of adjusted free cash flow in the second quarter of 2019, up 9% from the prior year and ahead of our expectations. Our performance highlights our stable and durable cash flow profile and allows us to remain committed to our deleveraging strategy to repay $1.1 billion of debt by the end of 2019. We also remain fully committed to maintaining our investment-grade credit rating.

Looking forward

Mylan reaffirmed its full-year 2019 guidance of total revenue between $11.5 billion and $12.5 billion. The company also continues to project adjusted EPS between $3.80 and $4.80, with adjusted free cash flow between $1.9 billion and $2.3 billion.

This outlook doesn't include any impact of the proposed combination with Pfizer's Upjohn unit because the transaction isn't expected to close until mid-2020. This merger will result in major changes for Mylan, though.

CEO Heather Bresch and CFO Ken Parks announced that they will leave Mylan after the transaction is completed. Michael Goettler, the current group president for Upjohn, will be the CEO of the new company, which will be renamed next year. Mylan president Rajiv Malik will serve as president of the combined company.

While investors' attention will rightly focus on the combination with Upjohn over the coming months, Mylan's improving revenue will still be a key thing to watch. Mylan's products will be important in the success of the new company that's on the way. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viatris Inc. Stock Quote
Viatris Inc.
Pfizer Inc. Stock Quote
Pfizer Inc.
$54.27 (2.32%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.